Lower Prescription Drug Costs
Trump administration expands drug pricing deals to lower prescription costs across America.
Anonymous
Key Points
1
Nine mid-sized manufacturers are part of the new MFN round: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
2
The MFN pricing pledges extend to every new innovative medicine these nine companies bring to market, ensuring MFN prices on all such products and limiting foreign price-control freeriding.
3
Participants commit to investing at least $19.6 billion in U.S. manufacturing in the near term as part of the MFN deals.
4
Smaller and mid-sized drugmakers have been slow to sign onto the MFN program, suggesting uneven uptake as the rollout continues.
5
Observers project potential federal and local government savings of about $64.3 billion over 10 years, though the actual impact remains unclear.
President Trump's administration is rapidly expanding its most-favored-nation drug pricing deals, now covering at least 26 manufacturers that represent the majority of the branded drug market Endpoints News. The latest round adds nine mid-sized companies—including Teva Pharmaceuticals, Sun Pharma, and CSL—to a voluntary program designed to lower prescription costs for Americans by rebalancing international pricing Hoodline. Participating firms dodge tariffs and gain access to federal programs in exchange for committing $19.6 billion in U.S. manufacturing investments Market Screener.
How Most-Favored-Nation Pricing Works
The MFN deals require drugmakers to offer U.S. Medicaid programs the lowest prices they charge any wealthy nation Hoodline. This forces companies to stop charging Americans far more than patients pay abroad. The nine newest signatories—Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB—commit to pricing all future innovative medicines under MFN terms Endpoints News.
Manufacturing Pledges and Strategic Reserves
Manufacturers joining the program pledge major domestic investments. The nine newest participants committed $19.6 billion toward U.S. manufacturing in the near term Market Screener. Several companies are also donating active pharmaceutical ingredients to a Strategic Reserve to reduce reliance on foreign suppliers and strengthen domestic pharmaceutical resilience Investing Live.
Projected Savings but Uneven Adoption
The White House projects federal and state government savings of roughly $64.3 billion over 10 years Investing Live. However, smaller and mid-sized drugmakers have signed on slowly, signaling patchy uptake across the industry. Analysts warn that actual out-of-pocket savings for patients remain unclear, and the program's real-world impact has yet to be measured Endpoints News.
Part of Broader Cost-of-Living Push
These MFN deals fit into Trump's wider TrumpRx healthcare agenda, designed to address cost-of-living pressures before the midterms Investing Live. Participants avoid tariffs and gain inclusion in favored federal programs—powerful incentives for signing on. The administration frames the rollout as ongoing, with Bayer, Takeda, and CSL announcements expected soon to deepen the program's reach Investing Live.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
106
Reach
125
A
AnonymousAuthor
